IFNG and neoplasm: Pharmacologic inhibition of RIP1 reprograms TAMs towards a MHCIIhiTNFα+IFNγ+ immunogenic phenotype in a STAT1-dependent manner, enhances cytotoxic T-cell activation, and impairs tumor growth in mice [155].